Janssen to Acquire XBiotech’s Bermekimab for $750M

 Janssen to Acquire XBiotech’s Bermekimab for $750M

Janssen to Acquire XBiotech’s Bermekimab for $750M

Shots:  

  • XBiotech to receive $750M up front and additional milestones upon certain commercialization authorizations. Janssen to get all rights for bermekimab and will conduct clinical program following the completion of ongoing P-II studies
  •  The focus of the acquisition is to fortify Janssen’s expertise in immuno-dermatology while expanding to AD and Hidradenitis Suppurativa (HS) targeting unmet medical needs. Additionally, Janssen has the rights to expand the indication of bermekimab beyond dermatology
  • Bermekimab is an investigational mAb targeting IL-1a, currently being evaluated in P-II study for AD and HS/ acne inversa

Click here to­ read full press release/ article | Ref: Janssen | Image: Bio news

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post